- Home
- TWIN vs ABOS Comparison
TWIN vs ABOS Comparison
Compare TWIN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- ABOS
- Stock Information
- Founded
- TWIN 1918
- ABOS 1996
- Country
- TWIN United States
- ABOS United States
- Employees
- TWIN N/A
- ABOS N/A
- Industry
- TWIN Industrial Machinery/Components
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- TWIN Industrials
- ABOS Health Care
- Exchange
- TWIN Nasdaq
- ABOS Nasdaq
- Market Cap
- TWIN 169.9M
- ABOS 166.4M
- IPO Year
- TWIN N/A
- ABOS 2021
- Fundamental
- Price
- TWIN $12.29
- ABOS $2.44
- Analyst Decision
- TWIN
- ABOS Strong Buy
- Analyst Count
- TWIN 0
- ABOS 4
- Target Price
- TWIN N/A
- ABOS $9.00
- AVG Volume (30 Days)
- TWIN 20.1K
- ABOS 160.3K
- Earning Date
- TWIN 10-31-2024
- ABOS 11-11-2024
- Dividend Yield
- TWIN 1.29%
- ABOS N/A
- EPS Growth
- TWIN 5.33
- ABOS N/A
- EPS
- TWIN 0.79
- ABOS N/A
- Revenue
- TWIN $295,127,000.00
- ABOS N/A
- Revenue This Year
- TWIN N/A
- ABOS N/A
- Revenue Next Year
- TWIN N/A
- ABOS N/A
- P/E Ratio
- TWIN $15.73
- ABOS N/A
- Revenue Growth
- TWIN 6.56
- ABOS N/A
- 52 Week Low
- TWIN $10.90
- ABOS $1.81
- 52 Week High
- TWIN $18.00
- ABOS $5.13
- Technical
- Relative Strength Index (RSI)
- TWIN 46.94
- ABOS 43.21
- Support Level
- TWIN $11.50
- ABOS $2.15
- Resistance Level
- TWIN $12.85
- ABOS $2.65
- Average True Range (ATR)
- TWIN 0.49
- ABOS 0.16
- MACD
- TWIN 0.03
- ABOS 0.00
- Stochastic Oscillator
- TWIN 45.66
- ABOS 37.58
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its products portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.